November 2012 Br J Cardiol 2012;19:158–9
News from the world of cardiology
The study, presented at the North American Menopause Society 2012 Annual Meeting held in Orlando, Florida, US, involved 700 women who took either oral conjugated equine oestrogens (Premarin®) 0.45 mg/day (lower than the 0.625 mg/day used in the Women’s Health Initiative [WHI] study), transdermal oestradiol (Climara®) 50 micrograms/day, or placebo. Women taking the active oestrogens received 200 mg of micronised progesterone for 12 days each month. As expected, both types of hormone therapy relieved menopausal symptoms, such as hot flushes and night sweats and had favourable effects on bone mineral density compared with placebo. WHI resu
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits